For study design, biostatistics and data management, big pharma trusts Brightech. Since 2002, we’ve worked with over 100 clients and completed 400+ projects in all phases. Our work has been a part of 30 NDA submissions with 6 obtaining FDA/EMA approval.
Our clients are our best salesmen. Our 120+ employee company doesn’t employ a single sales representative. Our clients stay with us and we have a 95% client retention rate.
Our thought-leadership in data services sets us apart in the industry. Our 10 PhD statisticians and Innovative Trial Design Group, which is overseen by KOPs, positions Brightech as one of the only company that knows FDA regulations and the proper statistical approach. While other midsize BDM CROs focus on SAS programming, Brightech helps sponsors design the most efficient studies, through regulatory to the final submission package.
70% of phase II studies fail, mostly because of study design, not the drug. Why not partner with a data driven CRO for a greater chance of success in the clinic? By taking a data driven approach with your study design, Brightech can help you eliminate the design risks that are causing your competitors’ studies to fail.
Brightech’s proprietary approach is driven by the combination of our unique people, processes and systems that have been validated in over 400 clinical studies.
Since our founding in 2002, our CEO Dr. Tai Xie has instilled a proactive, partner-like approach for each and every project. We strive to prove that sponsors can always rely on us, knowing that their study is in good hands.
Started in 2002 by founder and industry pioneer Dr. Tai Xie, Brightech has grown organically to 126 employees globally, with 30 in China, 16 Taiwan and 80+ people in New Jersey. We have 10 Ph.D. level statisticians who have an average of more than 16 years of pharmaceutical industry experience.
Brightech has extensive experience in a multitude of therapeutic areas, particularly oncology, cardiovascular disease, infectious disease, gastrointestinal disorder, CNS and analgesics; collaboration in numerous FDA/EMEA submissions.
With our expertise in complex studies, over 80% of our studies are in oncology.
We’re experts in SAS, a certified RAVE Medidata partner, and proficient in InForm. We also use CIMS, our proprietary complete EDC / eClinical solution that is unlike any other on the market.
